Candel Therapeutics, Inc.
CADL
$5.71
-$0.24-4.03%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 20.12M | 18.13M | 18.23M | 20.83M | 21.27M |
| Gross Profit | -20.12M | -18.13M | -18.23M | -20.83M | -21.27M |
| SG&A Expenses | 15.34M | 14.73M | 14.40M | 14.32M | 13.99M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.46M | 32.86M | 32.63M | 35.16M | 35.26M |
| Operating Income | -35.46M | -32.86M | -32.63M | -35.16M | -35.26M |
| Income Before Tax | -22.14M | -39.58M | -55.18M | -52.20M | -49.99M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -22.14 | -39.58 | -55.18 | -52.20 | -49.99 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.14M | -39.58M | -55.18M | -52.20M | -49.99M |
| EBIT | -35.46M | -32.86M | -32.63M | -35.16M | -35.26M |
| EBITDA | -34.49M | -31.87M | -31.64M | -34.16M | -34.27M |
| EPS Basic | -0.68 | -1.33 | -1.75 | -1.74 | -1.70 |
| Normalized Basic EPS | -0.41 | -0.82 | -1.08 | -1.08 | -1.05 |
| EPS Diluted | -0.69 | -1.34 | -1.75 | -1.74 | -1.70 |
| Normalized Diluted EPS | -0.42 | -0.82 | -1.08 | -1.08 | -1.05 |
| Average Basic Shares Outstanding | 169.55M | 147.94M | 126.65M | 120.07M | 116.98M |
| Average Diluted Shares Outstanding | 173.83M | 152.22M | 126.65M | 120.07M | 116.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |